MEDG Medgenics(Regs)

RNS Number:8253T
Medgenics Inc
07 May 2008

                                Medgenics, Inc.

                         ("Medgenics" or the "Company")



             MEDGENICS APPOINTS VICE PRESIDENT OF CLINICAL AFFAIRS



Misgav, Israel and London, UK - 7 May 2008 - Medgenics (AIM: MEDG), the
US-incorporated biopharmaceutical company, is pleased to announce that it has
appointed Dr. Ehud Shoshani, former CEO of Quintiles, Israel,  as its Vice
President of Clinical Affairs. Dr. Shoshani will manage the Company's Phase I/II
clinical trials with EPODURE, its lead sustained-action protein therapy to treat
anaemia, which is scheduled to start mid-2008 pending approval by the Israel
Ministry of Health (MoH).



Dr. Shoshani's 13 years' experience in managing clinical trials includes his
former position as Chief Executive Officer, Medical Director and Head of
Clinical Operations of the Israel division of Quintiles, the international
contract research organization.  In addition, he has served as Medical Director
at Omrix Biopharmaceutical, a blood products company (NASDAQ:OMRI), and at
Gamida Cell, a stem cell therapy company.



Dr. Shoshani was awarded his MD in 1978 from the Technion Medical School in
Haifa, Israel, and spent the next 16 years specializing in paediatrics,
paediatric oncology and haematology before entering industry.



Dr. Andrew Pearlman, Medgenics' CEO, said:



"We are extremely pleased that Dr. Shoshani has joined the team at this
important juncture for the Company. Building on the successful base of our
previous Phase I trial, Dr. Shoshani's extensive experience in managing clinical
trials will be highly valuable to Medgenics in completing the preparations, the
launch and the management of our imminent Phase I/II clinical trial for EPODURE.
  We look forward to benefiting from the breadth and depth of his clinical
development experience, in the development of our future clinical programmes for
this and our other pipeline products."



Dr. Ehud Shoshani said:



"Medgenics' biopump technology is a highly innovative approach to treating
chronic diseases and the preclinical and clinical data generated to date are, in
my view, very compelling. This gives me confidence that the forthcoming trials
with EPODURE will be successful, and will pave the way for future trials to
confirm the clinical value of this and other biopump-based protein therapies for
improving patient treatment by increasing efficacy and safety, reducing side
effects and eliminating frequent injections."



                                      ####

For further information, contact:


Medgenics, Inc.                                          Phone: +972 4 902 8900

Dr. Andrew L. Pearlman


Citigate Dewe Rogerson                                   Phone: +44 207 638 9571

Dr. Mark Swallow

Jonathan Shillington (Global Consulting Group)


Blomfield Corporate Finance Limited                      Phone: +44 207 512 0191

James Pinner

Alan MacKenzie





NOTES TO EDITORS:



About Medgenics



Medgenics, Inc. is a biopharmaceutical company developing its unique
tissue-based Biopump platform technology to provide sustained-action protein
therapy for the treatment of a range of chronic diseases.



Medgenics currently has two products in development based on this technology:



*    EPODURE - producing erythropoietin (EPO) to treat anaemia

*    INFRADURE - producing interferon-alpha (IFN-alpha) to treat
     hepatitis C



The Company has demonstrated proof of principle of the Biopump treatment
procedure in a clinical trial using a short-acting version of EPODURE in anaemic
patients. A long-acting version of EPODURE, designed to produce and deliver a
therapeutic dose of EPO steadily for six months or more, is scheduled to enter
Phase I/II trials in mid-2008. The Company plans to follow with clinical trials
of INFRADURE in 2009.



Medgenics intends to develop its innovative products and bring them to market
via multiple strategic partnerships with major pharmaceutical and/or medical
device companies, starting with EPODURE and INFRADURE.



Beyond these, Medgenics plans to develop and/or out-license a pipeline of future
Biopump products targeting the large and rapidly growing global protein therapy
market, which is forecast to reach US $87 billion by 2010. Other potential areas
include multiple sclerosis (interferon-beta), haemophilia (Factor XIII),
paediatric growth hormone deficiency (human growth hormone) and diabetes
(insulin).



Founded in 2000, Medgenics is a US-incorporated company with major operations in
Misgav, Israel. Medgenics was admitted to AIM in December 2007 (AIM: MEDG).



www.medgenics.com



CAUTIONARY NOTICE REGARDING FORWARD-LOOKING STATEMENTS

This release contains forward-looking statements, which include all statements
other than statements of historical fact, including (without limitation) those
regarding the Company's financial position, business strategy, plans and
objectives of management for future operations. These statements relate to
future events, prospects, developments and strategies. Forward-looking
statements are sometimes identified by their use of the terms and phrases such
as "estimate," "project," "intend," "forecast," "anticipate," "plan," "planning,
"expect," "believe," "will," "will likely," "should," "could," "would," "may" or
the negative of such terms and other comparable terminology. All such
forward-looking statements are based on current expectations and are subject to
risks and uncertainties. Should any of these risks or uncertainties materialize,
or should any of the Company's assumptions prove incorrect, actual results may
differ materially from those included within these forward-looking statements.
Accordingly, no undue reliance should be placed on these forward-looking
statements, which speak only as of the date made. The Company expressly
disclaims any obligation or undertaking to disseminate any updates or revisions
to any forward-looking statements contained herein to reflect any change in the
Company's expectations with regard thereto or any change in events, conditions
or circumstances on which any such statements are based. As a result of these
factors, the events described in the forward-looking statements contained in
this release may not occur.


                      This information is provided by RNS
            The company news service from the London Stock Exchange
END

MSCAFMRTMMBMBAP

Medgenics(Regs) (LSE:MEDG)
Historical Stock Chart
From May 2024 to Jun 2024

Medgenics(Regs) (LSE:MEDG)
Historical Stock Chart
From Jun 2023 to Jun 2024